Safecor Health Recalls 1,535 Ferrous Sulfate Oral Syringes Due to Defective Delivery System Leakage
Safecor Health, LLC, initiated a Class II recall for 1,535 units of Ferrous Sulfate 7.5 mg Oral Syringes due to leakage from a defective delivery system. This nationwide recall, D-0252-2025, highlights critical quality control issues in pharmaceutical repackaging. Procurement and regulatory teams must assess supply chain risks and ensure robust packaging integrity protocols to mitigate patient safety concerns.
FDA Class II Recall: Defective Delivery System for Ferrous Sulfate Oral Syringes
Safecor Health, LLC, a firm based in Columbus, OH, United States, has initiated a voluntary Class II recall, identified as D-0252-2025, for its Ferrous Sulfate 7.5 mg Iron/0.5 mL Oral Syringes. The recall, which commenced on February 17, 2025, stems from a critical quality defect: leakage observed in the oral solution after it was repackaged into unit-dose syringes. This issue directly impacts product integrity and patient safety, as a compromised delivery system can lead to inaccurate dosing or contamination. The affected product, also marketed as Iron Supplement Drops, was originally manufactured by Akron Pharma and subsequently repackaged by Safecor Health. A total of 1535 oral syringes are subject to this nationwide recall, distributed across the USA. This event underscores the imperative for robust quality control at every stage of the pharmaceutical supply chain, particularly for products requiring precise unit-dose delivery. Procurement directors must immediately quarantine any inventory matching the affected lot numbers and assess the potential for supply disruption for this essential iron supplement. Regulatory affairs heads should analyze this specific defect to benchmark their own packaging validation protocols, ensuring similar vulnerabilities are addressed proactively within their organizations.
Operational Impact: Safecor Health's Repackaging Role and Facility Details
Safecor Health, LLC, operating from its facility at 4060 Business Park Dr Ste B, Columbus, OH 43204-5047, plays a crucial role as a repackager within the pharmaceutical supply chain. This recall highlights the distinct responsibilities and quality challenges inherent in repackaging operations. While Akron Pharma manufactured the bulk Ferrous Sulfate solution, Safecor Health's process of transferring the oral solution into unit-dose syringes introduced the defective delivery system, leading to the observed leakage. The Class II classification by the FDA indicates that exposure to the defective product could cause temporary or medically reversible adverse health consequences, or that the probability of serious adverse health consequences is remote. For supply chain VPs, this incident serves as a critical reminder that quality assurance extends beyond the original manufacturer to every entity handling and preparing pharmaceutical products for final distribution. Thorough vetting of repackaging partners, including rigorous audits of their packaging lines and quality management systems, is paramount. Business development executives considering partnerships in the unit-dose packaging sector must conduct enhanced due diligence to ensure potential partners possess impeccable records in maintaining product integrity and delivery system functionality, thereby mitigating future recall risks.
Supply Chain Vulnerability for Ferrous Sulfate Oral Supplements
The nationwide distribution of 1535 affected Ferrous Sulfate 7.5 mg Iron/0.5 mL Oral Syringes creates a significant supply chain vulnerability for healthcare providers and patients relying on this specific iron supplement formulation. The recall encompasses multiple distinct lots, each with specific expiration dates: Lot #s 24250093 (Exp 03/07/2025), 24321592 (Exp 04/04/2025), 24280320 (Exp 03/27/2025), 24371268 (Exp 04/19/2025), 24400519 (Exp 04/07/2025), 24500768 (Exp 06/24/2025), and 25040972 (Exp 07/25/2025). Each of these lots is identifiable by specific NDC codes: 71399748005, 39328055750, and 69618007059. Procurement directors must leverage these precise identifiers to conduct immediate inventory checks and ensure all affected product is isolated and returned. The ongoing status of recall D-0252-2025 means that the market availability of this specific unit-dose presentation of Ferrous Sulfate may be constrained. Supply chain VPs should activate contingency plans, exploring alternative suppliers for oral iron supplements or different dosage forms to prevent potential stockouts and ensure continuity of patient care, especially for vulnerable populations requiring precise iron supplementation.
Broader Regulatory Scrutiny on Pharmaceutical Quality Systems
This recall by Safecor Health, LLC, while specific to a packaging defect, occurs within a broader landscape of intensified FDA scrutiny on pharmaceutical quality systems. Recent parallel events highlight this trend, such as the FDA Class II Recall of Essential Wellness Pharma's Progesterone Injection in June 2026 due to sterility assurance failures, and the FDA hearing impacting Amgen's Tavneos market future, also in June 2026, amid independent data review concerns. While these events involve different companies and product types, they collectively underscore the FDA's unwavering focus on manufacturing quality, product integrity, and data reliability across the entire life sciences sector. For regulatory affairs heads, this signals a need to continuously review and enhance Quality Management Systems (QMS) to meet evolving and stringent regulatory expectations, not just for manufacturing but also for critical downstream processes like repackaging. Business development executives should factor this heightened regulatory environment into their risk assessments for new product development, licensing agreements, and M&A activities, recognizing that quality and compliance issues can significantly impact market access and financial performance. Proactive investment in robust quality infrastructure is no longer merely a compliance cost but a strategic imperative for market resilience.
Immediate Actions and Future Compliance Expectations for Repackaging Firms
The ongoing status of recall D-0252-2025, initiated by Safecor Health, LLC, on February 17, 2025, mandates immediate and sustained action from the firm. Safecor Health is expected to conduct a thorough root cause investigation into the defective delivery system that led to the leakage of Ferrous Sulfate oral solution. This investigation must identify not only the immediate cause but also systemic issues in their repackaging processes, equipment, or quality control procedures. Subsequently, the firm will need to implement comprehensive corrective and preventive actions (CAPAs) and demonstrate their effectiveness to the FDA. For procurement directors, this means that any future engagement with Safecor Health or similar repackaging entities must include stringent requirements for transparency regarding recall resolution and verified CAPA implementation. Regulatory affairs teams should leverage this incident as a case study to reinforce internal training on packaging validation, in-process quality checks, and final product release criteria, particularly for liquid oral formulations. The FDA's continued oversight ensures that firms must maintain rigorous compliance, making proactive quality assurance a non-negotiable aspect of operations to avoid costly recalls and reputational damage.